Systematic Reviews
Copyright ©The Author(s) 2024.
World J Virol. Mar 25, 2024; 13(1): 88946
Published online Mar 25, 2024. doi: 10.5501/wjv.v13.i1.88946
Table 1 Baseline characteristics and patient demographics of the included studies (n = 7)
No.
Ref.
Study design
Study period
Country
Sample size, n (%)
Age, yr
Males, n (%)
Tumor size, cm
Cirrhosis, n
Tumor stage
Tumor grade
1Hai et al[11], 2005RetrospectiveJan 1997-Dec 2002JapanHCV+: 17; HCV-: 21HCV+: 69.0 ± 4.9; HCV-: 60.6 ± 12.4HCV+: 10; HCV-: 13HCV+: 3.6 ± 2.3; HCV-: 6.4 ± 4.5NRHCV+:I: 4, II: 4, III: 3, IV: 6; HCV-: I: 0, II: 6, III: 7, IV: 8NR
2Kaibori et al[19], 20211RetrospectiveJan 2000-Dec 2007JapanHCV+: 102; HCV-: 102HCV+: ≥ 70: 56/102; HCV-: ≥ 70: 59/102HCV+: 64; HCV-: 74HCV+: ≥ 3.5cm: 69/102; HCV-: ≥ 3.5cm: 61/102HCV+: 24; HCV-: 8 NRHCV+:well: 14, moderate: 49, poor: 27; HCV-: well: 21, moderate: 53, poor: 11
3Uenishi et al[20], 2014RetrospectiveJan 2000-Dec 2011JapanHCV+: 33
HCV-: 57
HCV+: 66.9 ± 9.0; HCV-: 64.3 ± 11.2HCV+: 23;
HCV-: 38
HCV+: 4.7 ± 1.7; HCV-: 4.8 ± 2.6HCV+: 14; HCV-: 3HCV+:I: 12, II: 7, III: 5, IV: 9; HCV-: I: 18, II: 9, III: 5, IV: 25HCV+: poor: 7; HCV-: poor: 7
4Cai et al[18], 2021RetrospectiveDec 2008-Dec 2017ChinaHCV+: 3; HCV-: 527NRNRNRNRNRNR
5Ariizumi et al[17], 2011Retrospective1989-2008JapanHCV+: 42; HCV-: 92NRNRNRNRNRNR
6Yang et al[21], 2019RetrospectiveJan 2005-Dec 2011ChinaHCV+: 1; HCV-: 167NRNRNRNRNRNR
7Terakawa et al[22], 2004RetrospectiveJan 1992-Dec 2001JapanHCV+: 7; HCV-: 10HCV+:64.0 ± 3.0; HCV-: 66.0 ± 3.0HCV+: 4; HCV-: 8HCV+: 5.0 ± 1.2; HCV-: 5.1 ± 1.0NRHCV+:II: 1, III: 3, IV: 3HCV-: II: 2, III: 4, IV: 4HCV+:well: 1, moderate: 4; HCV-: well: 1, moderate: 5